Eton Pharmaceuticals, Inc. (ETON)
NASDAQ: ETON · Real-Time Price · USD
18.95
-0.07 (-0.37%)
At close: Mar 13, 2026, 4:00 PM EDT
18.93
-0.02 (-0.11%)
After-hours: Mar 13, 2026, 5:17 PM EDT
Eton Pharmaceuticals Revenue
Eton Pharmaceuticals had revenue of $22.46M in the quarter ending September 30, 2025, with 117.54% growth. This brings the company's revenue in the last twelve months to $70.32M, up 102.77% year-over-year. In the year 2024, Eton Pharmaceuticals had annual revenue of $39.01M with 23.29% growth.
Revenue (ttm)
$70.32M
Revenue Growth
+102.77%
P/S Ratio
7.22
Revenue / Employee
$2,268,258
Employees
31
Market Cap
508.19M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 39.01M | 7.37M | 23.29% |
| Dec 31, 2023 | 31.64M | 10.39M | 48.90% |
| Dec 31, 2022 | 21.25M | -581.00K | -2.66% |
| Dec 31, 2021 | 21.83M | 21.79M | 55,879.49% |
| Dec 31, 2020 | 39.00K | -920.00K | -95.93% |
| Dec 31, 2019 | 959.00K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 837.32M |
| Emergent BioSolutions | 742.90M |
| Organogenesis Holdings | 564.17M |
| Esperion Therapeutics | 403.14M |
| Evolus | 297.18M |
| Ironwood Pharmaceuticals | 296.15M |
| Akebia Therapeutics | 236.20M |
| Canopy Growth | 203.04M |
ETON News
- 10 days ago - Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026 - GlobeNewsWire
- 11 days ago - Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution - GlobeNewsWire
- 16 days ago - US FDA approves Eton Pharma's hormonal disorder drug - Reuters
- 16 days ago - Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution - GlobeNewsWire
- 21 days ago - Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th - GlobeNewsWire
- 5 weeks ago - Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate - GlobeNewsWire
- 7 weeks ago - Eton Pharmaceuticals: An Undervalued Small Cap With High Growth - Seeking Alpha
- 3 months ago - Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th - GlobeNewsWire